What is Claimed is:

1. A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:



(I)

wherein one of R^1 and R^2 represents hydrogen atom and the other represents the formula $-X-A$ wherein A represents hydrogen atom or an acyl group, X represents oxgen atom or NH; one of R^3 and R^4 represents hydrogen atom and the other represents the following formula:



wherein Y represents a sulfonyl group or a carbonyl group, R^5 represents a cyclic group which may be substituted, Z represents a single bond or a C_1 to C_4 alkylene group which may be substituted, or when Z is substituted, said substituent may bind to R^5 to form a ring group, R^6 represents hydrogen atom or a C_1 to C_6 alkyl group which may be substituted, or R^6 may bind to Z or R^5 to form a cyclic group, provided that a compound represented by the following formula:



wherein each of A, Z, R^5 and R^5 has the same meaning as that defined above is excluded.

2. The medicament according to claim 1, wherein R^5 is an aromatic ring group

which may be substituted.

3. The medicament according to any one of claims 1 or 2, wherein Z is a methylene group which may be substituted, or when Z is substituted, said substituent may bind to R^5 to form a ring group.

4. The medicament according to any one of claims 1 to 3, wherein Y is a sulfonyl group.

5. The medicament according to any one of claims 1 to 4, wherein R^1 is a group represented by the formula $-O-A$ wherein A represents hydrogen atom or an acyl group, and R^2 is hydrogen atom.

6. The medicament according to any one of claims 1 to 5, wherein the cancer therapy based on the mode of action of DNA injury is carried out by an administration of an anticancer agent and/or radiation.

7. The medicament according to claim 6, wherein the anticancer agent is selected from the group consisting of bleomycin, adriamycin, cisplatin, cyclophosphamide, mitomycinC, and a derivative thereof.

8. The medicament according to any one of claims 1 to 7, which is a specific inhibitor of a protein kinase and/or an analogous enzyme thereof.

9. A medicament for reducing a side effect resulting from a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof according to claim 1.

10. A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof according to claim 1, provided that the following compound is excluded.



11. A compound selected from the group consisting of the following compounds or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate

thereof.

N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methylbenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[2-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,4-Dihydroxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Methoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,3-Dimethoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,5-Dimethoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,4-Methylenedioxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Aminobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Dimethylamino)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Cyclohexylmethyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Phenyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Benzyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Methylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[2-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-(3,4-Dihydroxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Methoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Methoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2,3-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3,5-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3,4-Methylenedioxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Aminobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Dimethylamino)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-Cyclohexylmethyl-5-hydroxynaphthalene-1-sulfonamide;

N-Phenyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-hydroxynaphthalene-1-sulfonamide;

5-Acetyloxy-N-benzylnaphthalene-2-sulfonamide;

5-Acetyloxy-N-(2,4-dichlorobenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(3-nitrobenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-[4-(trifluoromethyl)benzyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(3-aminobenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(1-naphthylmethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-[(5-methylfuran-2-yl)methyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-[(pyridin-2-yl)methyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-(cyclohexylmethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-phenylnaphthalene-2-sulfonamide;

5-Acetyloxy-N-(2-phenethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(1-phenethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-benzyl-N-methylnaphthalene-2-sulfonamide;

N-Benzyl-5-hydroxynaphthalene-2-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(3-Nitrobenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;

N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(3-Aminobenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(1-Naphthylmethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;

N-(Cyclohexylmethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-Phenyl-5-hydroxynaphthalene-2-sulfonamide;

N-(2-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(1-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-Benzyl-N-methyl-5-hydroxynaphthalene-2-sulfonamide;

5-Acetylamino-N-benzylnaphthalene-2-sulfonamide;

5-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

5-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Acetylamino-N-benzyl-N-methylnaphthalene-2-sulfonamide;

5-Amino-N-benzylnaphthalene-2-sulfonamide;

5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Amino-N-benzyl-N-methylnaphthalene-2-sulfonamide;

6-Acetylamino-N-benzylnaphthalene-1-sulfonamide;

6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;

6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;

6-Amino-N-benzylnaphthalene-1-sulfonamide;

6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;

6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;

6-Acetylamino-N-benzylnaphthalene-2-sulfonamide;

6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

6-Amino-N-benzylnaphthalene-2-sulfonamide;

6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Amino-N-benzylnaphthalene-1-carboxamide;

5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-carboxamide;

5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-carboxamide.

12. A medicament which comprises as an active ingredient a substance selected from the group consisting of a compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof according to claim 10 or 11.

13. A medicament according to claim 12, which is used for enhancing an effect of a cancer therapy based on a mode of action of DNA injury.